488 completed, 115 terminated, 115 unknown, 112 recruiting. 601 Phase 2, 210 Phase 1, 198 Phase 3, 21 Not applicable, 16 Phase 4.
Follow this drug Literature Review of Trastuzumab trials Research Report on Trastuzumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis Biopsy Procedure, Biospecimen Collection, Breast Conservation Treatment - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 562 | 2027-03-09 | 2026-10-13 |
| Trial of Retifanlimab With Trastuzumab and Pertuzumab Combination in HER2-Addicted Breast Cancer Retifanlimab, Trastuzumab (Herceptin), Pertuzumab - HER2-addicted Breast Cancer | Phase 2 | Not yet recruiting | Polly A. Niravath, MD | 30 | 2026-12-31 | 2026-08-19 |
| Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety. Alpelisib, Fulvestrant, Trastuzumab - PIK3CA-Related Overgrowth Spectrum (PROS), Breast Neoplasms (Including Advanced or Metastatic Breast Cancer With PIK3CA Mutation) | Phase 2 | Not yet recruiting | Novartis Pharmaceuticals | 51 | 2026-12-15 | 2026-09-18 |
| Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors Chimeric receptor T-cells + Trastuzumab, Fludarabine and Cyclophosphosphamide - HER2+ Advanced Breast Cancer, Other Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | National University Hospital, Singapore | 36 | 2026-11-01 | 2025-09-23 |
| A Phase II Study of HLX22 in Combination With Trastuzumab and Chemotherapy in HER2-Positive Locally Advanced or Metastatic Breast Cancer Patients HLX22, Trastuzumab, Capecitabine - HER2 + Breast Cancer | Phase 2 | Not yet recruiting | Shanghai Henlius Biotech | 90 | 2026-10-31 | 2026-09-17 |
| HER2-positive Breast Cancer Without Intravenous Neoadjuvant Therapy - Oral paclitaxel solution: 200 mg/m² orally twice daily on Day 1 and Day 8 of each cycle, subcutaneous pertuzumab and trastuzumab fixed-dose combination for a total of 6 cycles - HER 2 Positive Advanced Breast Cancer | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 65 | 2026-10-01 | 2026-09-30 |
| SHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Positive Early Breast Cancer After Pathologic Complete Response SHR-A1811, Trastuzumab, Pertuzumab - HER2-positive Breast Cancer, Early Breast Cancer (EBC) | Phase 2 | Not yet recruiting | Fudan University | 358 | 2026-10-01 | 2026-10-02 |
| Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast Cancer Fulvestaciclib, Trastuzumab, Pertuzumab - Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Not yet recruiting | Fudan University | 240 | 2026-10-01 | 2026-07-21 |
| Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast Cancer Trastuzumab Rezetecan, Pyrotinib, trastuzumab - HER2 + Breast Cancer, Advanced Breast Cancer | Phase 2 | Not yet recruiting | Fujian Cancer Hospital | 50 | 2026-09-30 | 2026-08-14 |
| T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd Trastuzumab deruxtecan, Trastuzumab, Pertuzumab - Advanced Breast Cancer, Metastatic Breast Cancer | Phase 3 | Recruiting | Daiichi Sankyo | 200 | 2026-09-18 | 2026-10-16 |
| Culmerciclib Combined With Letrozole and Dual HER2 Blockade as Neoadjuvant Therapy for HR+/HER2+ Breast Cancer Culmerciclib, Letrozole, Trastuzumab (TQB211) - Breast Cancer, HR Positive, HER2 Positive Breast Cancer | Phase 2 | Not yet recruiting | Shengjing Hospital | 33 | 2026-09-01 | 2026-08-31 |
| Clinical Trials Comparing Trastuzumab Plus Bevacizumab With Bevacizumab as First-line Maintenance Therapy for Epithelial Ovarian Cancer trastuzumab, bevacizumab - Ovarian Cancer | Phase 3 | Not yet recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 420 | 2026-09-01 | 2026-08-21 |
| Trastuzumab/Pertuzumab With Fulvestrant and Culmerciclib in HR+/HER2+ Early Breast Cancer Trastuzumab (or biosimilar), Pertuzumab, Culmerciclib - Breast Cancer | Phase 2 | Not yet recruiting | Hebei Medical University Fourth Hospital | 31 | 2026-09-01 | 2026-10-19 |
| Trial of Therapies With IT cDC1s Combined w/ IT Trastuzamab for Her+ or IT Nivolumab for Her- BC LMD cDC1 Vaccine, Trastuzumab, Nivolumab - Breast Cancer, Leptomeningeal Disease | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 30 | 2026-08-01 | 2026-07-10 |
| Paclitaxel Oral Solution in HER2-Positive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study Paclitaxel oral solution plus Trastuzumab and Pertuzumab - HER2 + Breast Cancer | Phase 1 / Phase 2 | Recruiting | Liu Shu | 30 | 2026-07-29 | 2026-08-04 |
| Asciminib in HER2+ Breast Cancer Brain Metastases Asciminib and Trastuzumab - HER2+ Metastatic Breast Cancer | Phase 1 / Phase 2 | Recruiting | Duke University | 42 | 2026-07-07 | 2026-07-22 |
| A Clinical Study Comparing Anti-HER2 Therapy Combined With Chemotherapy to Chemotherapy Alone as Adjuvant Therapy Following Surgery for Stage IB-II Gastric Cancer With High HER2 Expression. Trastuzumab, Monotherapy with tegafur for stage IB gastric cancer, Stage II gastric cancer treated with the SOX or XELOX regimens - IB-II Gastric Cancer | Phase 2 | Recruiting | Xijing Hospital | 120 | 2026-07-01 | 2026-08-26 |
| Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC Docetaxel, Pyrotinib, Trastuzumab (Herceptin) - Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Phase 3 | Recruiting | Shanghai Jiao Tong University School of Medicine | 220 | 2026-07-01 | 2026-09-01 |
| Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer Dalpiciclib, Trastuzumab (Herceptin), Pertuzumab - Advanced/Metastatic Breast Cancer, HER2-Positive Metastatic Breast Cancer | Phase 2 | Recruiting | Sun Yat-sen University | 57 | 2026-06-01 | 2026-05-28 |
| Study of Paclitaxel Polymeric Micelles Combined With HP and Adebelimab Versus Taxane Combined With HP as First-Line Treatment for Advanced HER2-Positive Breast Cancer Paclitaxel polymer micelles combined with trastuzumab, pertuzumab, and adrelumab, Taxanes combined with trastuzumab and pertuzumab. - Advanced HER2-positive Breast Cancer | Phase 2 | Not yet recruiting | Fudan University | 140 | 2026-06-01 | 2026-05-12 |
Showing 20 of 986. Sign in to see all of them.
Breast Neoplasms (643) · Stomach Neoplasms (77) · Neoplasm Metastasis (59) · Neoplasms (39) · Breast Neoplasms, Male (30) · Colorectal Neoplasms (28) · Brain Neoplasms (25) · Carcinoma, Non-Small-Cell Lung (21) · Esophageal Neoplasms (20) · Inflammatory Breast Neoplasms (20) · Pancreatic Neoplasms (13) · Triple Negative Breast Neoplasms (13) · Endometrial Neoplasms (11) · Lung Neoplasms (11) · Ovarian Neoplasms (11)
Hoffmann-La Roche (89) · National Cancer Institute (NCI) (44) · Fudan University (24) · Novartis Pharmaceuticals (24) · Memorial Sloan Kettering Cancer Center (19) · Dana-Farber Cancer Institute (18) · Genentech, Inc. (14) · M.D. Anderson Cancer Center (11) · SCRI Development Innovations, LLC (10) · City of Hope Medical Center (9) · NSABP Foundation Inc (9) · Pfizer (9) · H. Lee Moffitt Cancer Center and Research Institute (8) · Jonsson Comprehensive Cancer Center (8) · Sanofi (8)
United States (447) · China (206) · Spain (139) · France (134) · Italy (127) · Germany (116) · United Kingdom (95) · Belgium (91) · South Korea (91) · Canada (82) · Brazil (63) · Poland (61) · Australia (59) · Russia (55) · Taiwan (52)
Norman Wolmark, MD (9) · Nancy Lin, MD (8) · Denise A. Yardley, MD (4) · Mothaffar Rimawi, MD (4) · Yelena Janjigian, MD (4) · Adrienne Waks, MD (3) · Andrea De Matteis, M.D. (3)
PMID 26101239, PMID 20728210, PMID 28057664, PMID 39024777, PMID 39613746, PMID 10561296, PMID 15139054, PMID 16236737, PMID 16236738, PMID 17208639, PMID 21730275, PMID 22149875, PMID 22153890, PMID 22508812, PMID 23764181, PMID 24077916, PMID 2470152, PMID 25332249, PMID 26342236, PMID 26857702, PMID 27179402, PMID 29530935, PMID 29804905, PMID 30808774, PMID 31622131, PMID 33357420, PMID 33369581, PMID 34037241, PMID 34252375, PMID 35181666, PMID 35610260, PMID 35623069, PMID 37597578, PMID 38979716, PMID 39191270, PMID 39368039, PMID 40341124, PMID 10080589, PMID 10628376, PMID 10766175, PMID 11230490, PMID 11248153, PMID 11352950, PMID 11396203, PMID 11454999, PMID 11745247, PMID 12048273, PMID 12138395, PMID 12907602, PMID 12954578
2023 (14), 2009 (12), 2008 (11), 2014 (9), 2017 (8), U10CA180868 (8), 2018 (7), U10CA031946 (6), 2015 (5), P30CA033572 (5), P30CA015083 (4), P30CA016672 (4), U10CA012027 (4), U10CA021115 (4), 2005 (3)